886 related articles for article (PubMed ID: 23194489)
1. Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial.
Mentz RJ; Chung MJ; Gheorghiade M; Pang PS; Kwasny MJ; Ambrosy AP; Vaduganathan M; O'Connor CM; Swedberg K; Zannad F; Konstam MA; Maggioni AP
Am Heart J; 2012 Dec; 164(6):884-92.e2. PubMed ID: 23194489
[TBL] [Abstract][Full Text] [Related]
2. Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial).
Shah AN; Mentz RJ; Gheorghiade M; Kwasny MJ; Fought AJ; Zannad F; Swedberg K; Maggioni AP; Konstam MA
Am J Cardiol; 2012 Dec; 110(12):1803-8. PubMed ID: 22999071
[TBL] [Abstract][Full Text] [Related]
3. Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial).
Page RL; Connolly SJ; Crijns HJ; van Eickels M; Gaudin C; Torp-Pedersen C; Hohnloser SH;
Am J Cardiol; 2011 Apr; 107(7):1019-22. PubMed ID: 21296333
[TBL] [Abstract][Full Text] [Related]
4. Prevalence, pathophysiology, and clinical significance of post-heart transplant atrial fibrillation and atrial flutter.
Ahmari SA; Bunch TJ; Chandra A; Chandra V; Ujino K; Daly RC; Kushwaha SS; Edwards BS; Maalouf YF; Seward JB; McGregor CG; Chandrasekaran K
J Heart Lung Transplant; 2006 Jan; 25(1):53-60. PubMed ID: 16399531
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).
Greene SJ; Vaduganathan M; Lupi L; Ambrosy AP; Mentz RJ; Konstam MA; Nodari S; Subacius HP; Fonarow GC; Bonow RO; Gheorghiade M;
Am J Cardiol; 2013 Feb; 111(4):574-81. PubMed ID: 23206923
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
Vaduganathan M; Ambrosy AP; Greene SJ; Mentz RJ; Subacius HP; Maggioni AP; Swedberg K; Nodari S; Zannad F; Konstam MA; Butler J; Gheorghiade M;
Circ Heart Fail; 2012 Nov; 5(6):750-8. PubMed ID: 23051949
[TBL] [Abstract][Full Text] [Related]
7. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction.
Linssen GC; Rienstra M; Jaarsma T; Voors AA; van Gelder IC; Hillege HL; van Veldhuisen DJ
Eur J Heart Fail; 2011 Oct; 13(10):1111-20. PubMed ID: 21642293
[TBL] [Abstract][Full Text] [Related]
8. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
Ambrosy AP; Vaduganathan M; Mentz RJ; Greene SJ; Subačius H; Konstam MA; Maggioni AP; Swedberg K; Gheorghiade M
Am Heart J; 2013 Feb; 165(2):216-25. PubMed ID: 23351825
[TBL] [Abstract][Full Text] [Related]
9. Presence of atrial fibrillation is independently associated with adverse outcomes in patients hospitalized with heart failure: an analysis of get with the guidelines-heart failure.
Mountantonakis SE; Grau-Sepulveda MV; Bhatt DL; Hernandez AF; Peterson ED; Fonarow GC
Circ Heart Fail; 2012 Mar; 5(2):191-201. PubMed ID: 22361078
[TBL] [Abstract][Full Text] [Related]
10. Incidence, risk factors, and clinical outcomes of atrial fibrillation and atrial flutter after heart transplantation.
Dasari TW; Pavlovic-Surjancev B; Patel N; Williams AA; Ezidinma P; Rupani A; Sinacore JL; Heroux AL
Am J Cardiol; 2010 Sep; 106(5):737-41. PubMed ID: 20723655
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).
Greene SJ; Harinstein ME; Vaduganathan M; Subačius H; Konstam MA; Zannad F; Maggioni AP; Swedberg K; Butler J; Gheorghiade M;
Am J Cardiol; 2012 Dec; 110(11):1657-62. PubMed ID: 22917555
[TBL] [Abstract][Full Text] [Related]
12. Celivarone for maintenance of sinus rhythm and conversion of atrial fibrillation/flutter.
Khitri AR; Aliot EM; Capucci A; Connolly SJ; Crijns H; Hohnloser SH; Kulakowski P; Roy D; Radzik D; Kowey PR
J Cardiovasc Electrophysiol; 2012 May; 23(5):462-72. PubMed ID: 22171925
[TBL] [Abstract][Full Text] [Related]
13. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial.
Blair JE; Pang PS; Schrier RW; Metra M; Traver B; Cook T; Campia U; Ambrosy A; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Konstam MA; Gheorghiade M;
Eur Heart J; 2011 Oct; 32(20):2563-72. PubMed ID: 21785107
[TBL] [Abstract][Full Text] [Related]
14. Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial.
O'Meara E; Khairy P; Blanchet MC; de Denus S; Pedersen OD; Levesque S; Talajic M; Ducharme A; White M; Racine N; Rouleau JL; Tardif JC; Roy D;
Circ Heart Fail; 2012 Sep; 5(5):586-93. PubMed ID: 22798522
[TBL] [Abstract][Full Text] [Related]
15. History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure.
Patel RB; Vaduganathan M; Rikhi A; Chakraborty H; Greene SJ; Hernandez AF; Felker GM; Redfield MM; Butler J; Shah SJ
JACC Heart Fail; 2019 Jan; 7(1):47-55. PubMed ID: 30409707
[TBL] [Abstract][Full Text] [Related]
16. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
Haywood LJ; Ford CE; Crow RS; Davis BR; Massie BM; Einhorn PT; Williard A;
J Am Coll Cardiol; 2009 Nov; 54(22):2023-31. PubMed ID: 19926008
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of cardiac resynchronization therapy in patients with intermittent atrial fibrillation or atrial flutter in the COMPANION trial.
Kalscheur MM; Saxon LA; Lee BK; Steinberg JS; Mei C; Buhr KA; DeMets DL; Bristow MR; Singh SN
Heart Rhythm; 2017 Jun; 14(6):858-865. PubMed ID: 28323173
[TBL] [Abstract][Full Text] [Related]
18. Atrial flutter or fibrillation is the most frequent and life-threatening arrhythmia in myotonic dystrophy.
Brembilla-Perrot B; Schwartz J; Huttin O; Frikha Z; Sellal JM; Sadoul N; Blangy H; Olivier A; Louis S; Kaminsky P
Pacing Clin Electrophysiol; 2014 Mar; 37(3):329-35. PubMed ID: 24117873
[TBL] [Abstract][Full Text] [Related]
19. Predictors and prognostic implications of incident heart failure following the first diagnosis of atrial fibrillation in patients with structurally normal hearts: the Belgrade Atrial Fibrillation Study.
Potpara TS; Polovina MM; Licina MM; Marinkovic JM; Lip GY
Eur J Heart Fail; 2013 Apr; 15(4):415-24. PubMed ID: 23302606
[TBL] [Abstract][Full Text] [Related]
20. Temporal pattern and costs of rehospitalization in atrial fibrillation/atrial flutter patients with one or more additional risk factors.
Amin AN; Jhaveri M; Lin J
J Med Econ; 2012; 15(3):548-55. PubMed ID: 22352988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
